At IPI, we pioneer pharmaceutical and healthcare advancements globally through strategic partnerships, uniting expertise to develop cutting-edge solutions, enhance patient care, and tackle diverse healthcare challenges.

During our attendance at the World Pharmaceutical Components Conference (#IPIpharma) in Barcelona, Spain, we proudly presented our Iraqi-produced medicines (#CPhI). We also engaged in a wide range of discussions, covering topics from the next generation of biomanufacturing to innovations in sustainable solutions within the pharmaceutical sector.

The Iraqi Blood Diseases Summit in Basra brought together leading experts and doctors to collaborate on advancing the field. It aimed to drive progress in research, diagnosis, and treatment methods for blood disorders, ultimately improving healthcare outcomes.

The launching conference of the Iraqi Pharmaceutical Industry Company showcased a 90% attendance rate among healthcare providers, underscoring our dedication to delivering high-quality oncology and hematology medications. This event culminated in a strategic partnership aimed at advancing healthcare standards in Iraq.

We are proud to continue setting new benchmarks in the pharmaceutical industry. In a historic achievement for Iraq, we have authorized PHARMACARE to manufacture Palbociclib IPI, a vital breast cancer medication. This pivotal development has attracted considerable attention from the media.

Iraq's pharmaceutical industry has achieved a significant milestone by locally producing cancer drugs for the first time. Under the guidance of Minister of Health Dr. Saleh Al-Hasnawi, the Ministry has partnered with Iraqi factories to improve medicine production. The Iraq Pharmaceutical Industry (IPI), established in 1954, meets European standards and has notably reduced costs. This accomplishment brings Iraq one step closer to pharmaceutical self-sufficiency, guaranteeing quality healthcare for its citizens.